KOD
$23.85
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Recent News
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Weakness And Strong One Year Return
Kodiak Sciences overview and recent performance snapshot Kodiak Sciences (KOD) has drawn investor attention recently, with shares closing at US$23.19 and showing mixed return patterns, including a 1 day decline of 2.5% and a 6.7% drop over the past week. See our latest analysis for Kodiak Sciences. While the 1 day and 7 day share price returns of 2.5% and 6.7% declines hint at fading short term momentum around US$23.19, the 1 year total shareholder return, which is more than six times the...
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.